DA-9501 (Dexmedetomidine) for Sedation in Non-Intubated Patients

Phase 3, randomised, double-blind trial of dexmedetomidine in Procedural sedation (PS) (3 arms), sponsored by Pfizer. Primary endpoint: Incidence of patients who did not require rescue administration of propofol to achieve and maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4. Started Jul 2011; status: completed.